| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 3,634,407 | 2,268,427 | 1,052,898 | - |
| Cost of product revenues (including definite-lived intangible amortization) | 250,955 | 151,954 | 73,188 | - |
| Contract dispute settlement | 242,251 | 242,251 | - | - |
| Research and development - internal | 715,171 | 465,031 | 228,345 | - |
| Research and development - external | 695,459 | 439,115 | 193,434 | - |
| Other research and development | 28,150 | 28,050 | 15,500 | - |
| Sales and marketing | 786,265 | 513,963 | 257,652 | - |
| General and administrative | 199,529 | 142,750 | 68,039 | - |
| (gain) loss on change in fair value of acquisition-related contingent consideration | 22,129 | 34,333 | 11,572 | - |
| (profit) and loss sharing under collaboration agreements | 0 | 0 | 0 | - |
| Other segment items | 191,629 | 172,280 | 46,965 | - |
| Net income (loss) | 987,371 | 563,202 | 158,203 | -168,597 |
| Depreciation and amortization | 69,304 | 45,281 | 22,362 | 66,515 |
| Stock-based compensation | 187,189 | 125,591 | 60,982 | 194,340 |
| Deferred income taxes | -234,188 | -110,071 | 6,706 | 85,609 |
| Other, net | -3,445 | 3,220 | -5,292 | 4,824 |
| (gain) on equity investments | 3,064 | -5,494 | -1,343 | 126,206 |
| Loss on change in fair value of acquisition-related contingent consideration | 22,129 | 34,333 | 11,572 | 23,847 |
| Accounts receivable | 42,275 | -10,726 | -30,955 | 14,893 |
| Prepaid expenses and other assets | 221,275 | 148,440 | 62,045 | 55,381 |
| Inventory | 53,654 | 48,099 | 28,574 | 93,352 |
| Accounts payable | -26,414 | 17,752 | -2,159 | 69,109 |
| Accrued and other liabilities | -286,747 | -401,883 | 74,842 | 149,170 |
| Net cash provided by (used in) operating activities | 870,197 | 310,808 | 266,067 | -45,881 |
| Purchase of long term investments | - | - | - | 0 |
| Sale of equity investments | 8 | 7 | 8 | 282,866 |
| Capital expenditures | 36,990 | 22,243 | 3,169 | 68,879 |
| Payments for intangible assets | 25,000 | 0 | - | 13,900 |
| Purchases of marketable securities | 212,852 | 97,346 | 41,236 | 228,986 |
| Maturities of marketable securities | 209,643 | 101,807 | 45,494 | 207,881 |
| Net cash (used in) provided by investing activities | -65,191 | -17,775 | 1,097 | 178,982 |
| Repurchases of common stock | 0 | 0 | - | 2,004,790 |
| Excise tax paid on repurchase of common stock | 19,100 | 19,100 | - | - |
| Proceeds from issuance of common stock under stock plans | 61,553 | 18,123 | 3,239 | 16,242 |
| Tax withholdings related to restricted and performance share vesting | 60,469 | 10,366 | 9,454 | 39,416 |
| Payment of finance lease liabilities | 3,386 | 2,245 | 1,090 | 2,761 |
| Payment of contingent consideration | 15,298 | 10,334 | 5,371 | 11,216 |
| Net cash used in financing activities | -36,700 | -23,922 | -12,676 | -2,041,941 |
| Effect of exchange rates on cash, cash equivalents, and restricted cash | -908 | -1,749 | -552 | -535 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 767,398 | 267,362 | 253,936 | -1,909,375 |
| Cash and cash equivalents at beginning of period | 1,689,451 | 1,689,451 | 1,689,451 | 3,215,221 |
| Cash and cash equivalents at end of period | 2,456,849 | 1,956,813 | 1,943,387 | 1,305,846 |
INCYTE CORP (INCY)
INCYTE CORP (INCY)